Literature DB >> 20621595

[Assessment of azoospermia and histological evaluation of spermatogenesis].

Geoffroy Robin1, Florence Boitrelle, Xavier Leroy, Marie-Claire Peers, François Marcelli, Jean-Marc Rigot, Valérie Mitchell.   

Abstract

Azoospermia may be obstructive (blockage of the genital ducts) or non-obstructive (a lack of testicular production). The distinction is based on an ensemble of clinical, spermiological, hormonal, ultrasound, genetic and histological data. Azoospermia is the main indication for testicular biopsy for therapeutic and diagnostic purposes. Testicular spermatozoids are processed in the reproductive biology laboratory (simultaneously with oocyte retrieval or not) for in vitro fertilization with intra-cytoplasmic sperm injection. The histological study of spermatogenesis is usually performed on a testicular biopsy sample taken at the same time and provides additional diagnostic information on infertility. Histological alterations in the testicular tissues are frequently observed in azoospermic men. In non-obstructive azoospermia, three histological situations prevail: hypospermatogenesis, Sertoli-cell-only syndrome and germ cell arrest. One can distinguish between pure forms (in which all the seminiferous tubules have the same appearance) and mixed forms (in which the tubules' aspects are heterogeneous). Hypospermatogenesis is highly prevalent in azoospermia and is characterized by a low, basal level of spermatozoid production. The prevalence of Sertoli-cell-only syndrome varies from 27 to 68% and the mean spermatozoid recovery rate is between 16 and 33%. Germ cell arrests are rare phenotypes and have a poor prognosis for spermatozoid recovery. Overall, histological examination (still the only way to fully describe spermatogenesis) must be qualitative and quantitative, with the adoption of a standardized, universally understood terminology. It is essential to compare the histological data with (i) recovery of testicular spermatozoids, (ii) clinical, ultrasound, hormonal and genetic data and (iii) the outcome of IVF/ICSI procedures. 2010 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20621595     DOI: 10.1016/j.annpat.2010.03.015

Source DB:  PubMed          Journal:  Ann Pathol        ISSN: 0242-6498            Impact factor:   0.407


  6 in total

1.  A clinical trial on the consistency of bilateral testicular tissue histopathology and Johnsen score: single side or bilateral side biopsy?

Authors:  Wen-Hao Tang; Shan-Jie Zhou; Shi-De Song; Hui-Ying He; Han Wu; Zhe Zhang; Yu-Zhuo Yang; Hong-Liang Zhang; Jia-Ming Mao; De-Feng Liu; Lian-Ming Zhao; Hao-Cheng Lin; Kai Hong; Lu-Lin Ma; Xin-Jie Zhuang; Hui Jiang
Journal:  Oncotarget       Date:  2018-05-08

2.  Genetic defects in human azoospermia.

Authors:  Farah Ghieh; Valérie Mitchell; Béatrice Mandon-Pepin; François Vialard
Journal:  Basic Clin Androl       Date:  2019-04-23

3.  PGAM1 knockdown is associated with busulfan‑induced hypospermatogenesis and spermatogenic cell apoptosis.

Authors:  Yuanshu Zhao; Shoubo Zhang
Journal:  Mol Med Rep       Date:  2019-02-04       Impact factor: 2.952

4.  Phosphoribosyl-pyrophosphate synthetase 2 (PRPS2) depletion regulates spermatogenic cell apoptosis and is correlated with hypospermatogenesis.

Authors:  Bin Lei; Li-Xia Xie; Shou-Bo Zhang; Bo Wan; Li-Ren Zhong; Xu-Ming Zhou; Xiang-Ming Mao; Fang-Peng Shu
Journal:  Asian J Androl       Date:  2020 Sep-Oct       Impact factor: 3.285

5.  For patients with non-obstructive azoospermia, the outcome of testicular sperm extraction correlates with self-esteem, sexual health and the quality of the couple's relationship.

Authors:  Marion Bendayan; Emine Sais; Laura Alter; Khadija Fathallah; Monique Jaoul; Pierre Olivier Bosset; Geoffroy Robin; Florence Boitrelle
Journal:  Basic Clin Androl       Date:  2022-02-16

Review 6.  Progress and future prospect of in vitro spermatogenesis.

Authors:  Fahar Ibtisham; Jiang Wu; Mei Xiao; Lilong An; Zachary Banker; Aamir Nawab; Yi Zhao; Guanghui Li
Journal:  Oncotarget       Date:  2017-07-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.